358 related articles for article (PubMed ID: 29903894)
1. Novel Approaches to Acute Myeloid Leukemia Immunotherapy.
Beyar-Katz O; Gill S
Clin Cancer Res; 2018 Nov; 24(22):5502-5515. PubMed ID: 29903894
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
3. Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia.
Agrawal V; Gbolahan OB; Stahl M; Zeidan AM; Zaid MA; Farag SS; Konig H
Curr Cancer Drug Targets; 2020; 20(7):473-489. PubMed ID: 32357813
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors in AML-A New Frontier.
Thummalapalli R; Knaus HA; Gojo I; Zeidner JF
Curr Cancer Drug Targets; 2020; 20(7):545-557. PubMed ID: 32316893
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukaemia and the immune system: implications for immunotherapy.
Barrett AJ
Br J Haematol; 2020 Jan; 188(1):147-158. PubMed ID: 31782805
[TBL] [Abstract][Full Text] [Related]
6. Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia.
Goswami M; Hourigan CS
Curr Drug Targets; 2017; 18(3):296-303. PubMed ID: 25706110
[TBL] [Abstract][Full Text] [Related]
7. The progress and current status of immunotherapy in acute myeloid leukemia.
Yang D; Zhang X; Zhang X; Xu Y
Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu Y; Bewersdorf JP; Stahl M; Zeidan AM
Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
[TBL] [Abstract][Full Text] [Related]
9. Catch me if you can: how AML and its niche escape immunotherapy.
Tettamanti S; Pievani A; Biondi A; Dotti G; Serafini M
Leukemia; 2022 Jan; 36(1):13-22. PubMed ID: 34302116
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia.
Morsink LM; Walter RB; Ossenkoppele GJ
Blood Rev; 2019 Mar; 34():26-33. PubMed ID: 30401586
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia.
Tallman M
J Natl Compr Canc Netw; 2018 May; 16(5S):656-659. PubMed ID: 29784749
[TBL] [Abstract][Full Text] [Related]
12. Cancer immune therapy for myeloid malignancies: present and future.
Holmström MO; Hasselbalch HC
Semin Immunopathol; 2019 Jan; 41(1):97-109. PubMed ID: 29987478
[TBL] [Abstract][Full Text] [Related]
13. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
14. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
Venugopal S; Daver N; Ravandi F
Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
[TBL] [Abstract][Full Text] [Related]
15. Opportunities for immunotherapy in childhood acute myeloid leukemia.
Lamble AJ; Tasian SK
Blood Adv; 2019 Nov; 3(22):3750-3758. PubMed ID: 31770440
[TBL] [Abstract][Full Text] [Related]
16. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
Hattori N; Nakamaki T
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
[TBL] [Abstract][Full Text] [Related]
17. Advances in targeted therapy for acute myeloid leukaemia.
Kayser S; Levis MJ
Br J Haematol; 2018 Feb; 180(4):484-500. PubMed ID: 29193012
[TBL] [Abstract][Full Text] [Related]
18. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
Ganesan R; Chennupati V; Ramachandran B; Hansen MR; Singh S; Grewal IS
Leukemia; 2021 Aug; 35(8):2274-2284. PubMed ID: 33526858
[TBL] [Abstract][Full Text] [Related]
19. Immune-Based Therapies in Acute Leukemia.
Witkowski MT; Lasry A; Carroll WL; Aifantis I
Trends Cancer; 2019 Oct; 5(10):604-618. PubMed ID: 31706508
[TBL] [Abstract][Full Text] [Related]
20. Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
McMahon CM; Perl AE
Leuk Lymphoma; 2019 Mar; 60(3):583-597. PubMed ID: 30234399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
